News – Page 7 – Endpoints News

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

3 weeks ago

Illumina confirms SEC has closed investigation into $8B Grail deal

3 weeks ago

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

3 weeks ago

Illumina forecasts $85M in tariff costs, decrease in China sales

3 weeks ago

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

3 weeks ago

AstraZeneca loses appeals court fight over IRA drug price negotiations

3 weeks ago

GSK awaits Nucala decision after FDA target date passes

3 weeks ago

FDA grants Verastem first approval for rare ovarian cancer treatment

3 weeks ago

Bristol Myers' $40B US investment; Shionogi to buy Japanese drugmaker

3 weeks ago

ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffs

3 weeks ago

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

3 weeks ago

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

3 weeks ago

HAYA Therapeutics gets $65M for 'dark genome' work following last year's Lilly pact

3 weeks ago

Lantheus culls late-stage Lilly-partnered prostate cancer radioligand

3 weeks ago

FDA will convene vaccine advisors to discuss Covid strain updates

3 weeks ago

Gilead reveals plans to put another $11B into US manufacturing

3 weeks ago

Teva plans staff cuts as it commits to accelerating growth

3 weeks ago

PhRMA says tariffs are 'not the answer' as industry trade probe closes for comments

3 weeks ago

FDA's ODAC will review drugs for four different cancers at meeting in May

3 weeks ago

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling

3 weeks ago

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

3 weeks ago

Compounders just lost their case to put obesity drug tirzepatide back in shortage

3 weeks ago

Charles River launches ‘strategic review’ alongside activist investor Elliott

3 weeks ago

European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue

3 weeks ago

First page Previous page 4 5 678 9 10 Next page Last page